title: Reply to: "Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors".
authors.affiliation: The Permanente Medical Group, Kaiser Permanente, Roseville, California.
authors.forename: Sean D
authors.initials: SD
authors.lastname: Doherty
authors.affiliation: University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
authors.forename: Abby S
authors.initials: AS
authors.lastname: Van Voorhees
authors.affiliation: Mt Sinai School of Medicine, New York, New York.
authors.forename: Mark G
authors.initials: MG
authors.lastname: Lebwohl
authors.affiliation: Case Western Reserve University School of Medicine, Cleveland, Ohio.
authors.forename: Neil J
authors.initials: NJ
authors.lastname: Korman
authors.affiliation: Baylor College of Medicine, Houston, Texas. Electronic address: shsu@bcm.edu.
authors.forename: Sylvia
authors.initials: S
authors.lastname: Hsu
mesh_terms: D001691:Biological Therapy / Q000009:adverse effects*; D003141:Communicable Diseases / Q000150:complications* / Q000175:diagnosis*; D006801:Humans; D012871:Skin Diseases / Q000150:complications* / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D014409:Tumor Necrosis Factor-alpha